A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period
研究概览
简要总结
This Phase I behavior therapy development study seeks to improve treatment outcomes for methamphetamine (MA)-dependent subjects by developing a novel cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •English-speaking adults ≥ 18 years who are seeking treatment for MA addiction.
- •Own a cellular phone with SMS text messaging capability and have an unlimited text messaging plan.
- •Available to attend CBT therapy groups.
- •Agreeable to conditions of the study and signed an informed consent form.
排除标准
- •Projected to be unavailable > 12 hours/day to read and send text messages.
- •Any medical or psychosocial condition that would preclude safe, useful, or consistent participation,
研究组 & 干预措施
CBT- based SMS text messaging intervention
cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
干预措施: CBT group therapy (Behavioral)
CBT- based SMS text messaging intervention
cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
干预措施: CBT- based SMS text messaging intervention (Behavioral)
Placebo Texts
Placebo texts will be given instead of interventional texts
干预措施: CBT group therapy (Behavioral)
结局指标
主要结局
Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period
时间窗: 5 weeks
The primary efficacy measure for this study is the difference in proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period. Urine samples will be analyzed for MA by immunoassay with a cutoff of 1,000 ng/mL.
次要结局
未报告次要终点
研究者
Gantt Galloway, PharmD
Senior Scientist
California Pacific Medical Center Research Institute